Sight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Rating of "Hold" by Brokerages

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) has been given a consensus recommendation of "Hold" by the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $3.83.

SGHT has been the subject of several analyst reports. Stifel Nicolaus lowered their price objective on Sight Sciences from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Piper Sandler lowered their price target on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating for the company in a report on Thursday, March 6th. Lake Street Capital raised their price objective on shares of Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a report on Friday. Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Finally, Citigroup dropped their target price on shares of Sight Sciences from $4.60 to $3.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th.

Sight Sciences Stock Down 2.6 %

NASDAQ:SGHT traded down $0.08 during mid-day trading on Monday, hitting $2.95. The stock had a trading volume of 120,766 shares, compared to its average volume of 236,017. Sight Sciences has a twelve month low of $2.03 and a twelve month high of $8.45. The stock has a 50-day simple moving average of $2.67 and a two-hundred day simple moving average of $3.26. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $152.50 million, a PE ratio of -2.89 and a beta of 2.41.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. The business had revenue of $17.51 million for the quarter, compared to analyst estimates of $16.51 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. On average, equities research analysts anticipate that Sight Sciences will post -0.99 EPS for the current year.

Insider Transactions at Sight Sciences

In related news, EVP Manohar K. Raheja acquired 10,000 shares of Sight Sciences stock in a transaction on Wednesday, March 12th. The stock was purchased at an average cost of $2.73 per share, with a total value of $27,300.00. Following the purchase, the executive vice president now directly owns 145,000 shares in the company, valued at approximately $395,850. The trade was a 7.41 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Paul Badawi sold 24,174 shares of the stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total value of $55,600.20. Following the sale, the chief executive officer now directly owns 6,010,580 shares of the company's stock, valued at $13,824,334. The trade was a 0.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,196 shares of company stock worth $81,001. Insiders own 28.90% of the company's stock.

Institutional Investors Weigh In On Sight Sciences

Several large investors have recently modified their holdings of the stock. KCK LTD. acquired a new position in Sight Sciences in the 4th quarter valued at $15,925,000. Barclays PLC increased its position in Sight Sciences by 317.4% during the 3rd quarter. Barclays PLC now owns 50,300 shares of the company's stock worth $317,000 after purchasing an additional 38,248 shares during the period. Geode Capital Management LLC raised its stake in shares of Sight Sciences by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company's stock worth $4,941,000 after buying an additional 12,709 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Sight Sciences by 654.3% in the 4th quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock valued at $1,431,000 after buying an additional 340,906 shares during the period. Finally, American Century Companies Inc. boosted its stake in shares of Sight Sciences by 10.7% in the fourth quarter. American Century Companies Inc. now owns 51,564 shares of the company's stock valued at $188,000 after buying an additional 4,964 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company's stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.